Payers worldwide recognize the value of patient reported outcomes (PRO) data in decision making. But what are the characteristics of data that most strongly influence payer decision making? And what impact does that data have on reimbursement decisions and market access?
These are timely questions, as PRO data is expected to continue growing in influence. A study just published in the Journal of Managed Care Pharmacy and coauthored by four RTI Health Solutions researchers (see below), Payer perspectives on patient-reported outcomes in health care decision making: oncology examples, addresses these questions in the area of oncology research.
Researchers conducted a targeted literature review, interviews with payers from the RTI Health Solutions global advisory panel, and an online assessment to gather information. Results suggested that PRO data may be especially beneficial in oncology, and that postprogression data could potentially help with treatment differentiation.
The study reports that the most influential PRO data has these characteristics:
• Quality, well-controlled, transparent evidence
• Psychometric validation
• Peer-reviewed journal publication